Upcoming Product Portfolio

An expanding portfolio of upcoming pharmaceutical products in collaboration with globally recognized manufacturers, with continued focus on oncology and other critical therapeutic areas.

Future Therapeutic Excellence Through Partnership

Our upcoming product pipeline represents strengthening partnerships with international pharmaceutical manufacturers. These future additions will be introduced through ethical marketing practices, strict regulatory compliance, and strong institutional engagement across Pakistan ensuring continued advancement in patient care and treatment access.

2026 (MARCH)

nelalidomide

Nelalidomide

Generic -----
Indications -----
Dosage -----
Category -----
Palbociclib

Palbociclib

Generic -----
Indications -----
Dosage -----
Category -----
Enzalutamide

Enzalutamide

Generic -----
Indications -----
Dosage -----
Category -----
osimertinib

Osimertinib

Generic -----
Indications -----
Dosage -----
Category -----

2026 (AUGUST)

pomalidomide

Pomalidomide

Generic -----
Indications -----
Dosage -----
Category -----
bevacizumab

Bevacizumab

Generic -----
Indications -----
Dosage -----
Category -----
peg-filgrastim

Peg-filgrastim

Generic -----
Indications -----
Dosage -----
Category -----
trastuzumab

Trastuzumab

Generic ----
Indications -----
Dosage -----
Category -----

2026 (December)

temozolomide

Temozolomide

Generic -----
Indications -----
Dosage -----
Category -----
lemvatinib

Lemvatinib

Generic -----
Indications -----
Dosage -----
Category -----
abemaciclib

Abemaciclib

Generic -----
Indications -----
Dosage -----
Category -----

2027 (April)

Lomustine

Nivolumav

Generic ------
Indications -----
Dosage -----
Category -----
Tembrolizumab

Tembrolizumab

Generic -----
Indications -----
Dosage ------
Category -----
denosumab

Denosumab

Generic ------
Indications ------
Dosage ------
Category ------

Interested in Our Portfolio?

For detailed product information or partnership inquiries, please contact our team.

Contact Us
WhatsApp